Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID‐19: A Large Case‐Control Study
This study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of coronavirus disease 2019 (COVID‐19) in a cohort of 610 COVID‐19 cases and 48,667 population‐based controls from Zhejiang, China. Using a cohort of 5...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacology and therapeutics 2020-12, Vol.108 (6), p.1185-1194 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | This study aimed to investigate whether specific medications used in the treatment chronic diseases affected either the development and/ or severity of coronavirus disease 2019 (COVID‐19) in a cohort of 610 COVID‐19 cases and 48,667 population‐based controls from Zhejiang, China. Using a cohort of 578 COVID‐19 cases and 48,667 population‐based controls from Zhejiang, China, we tested the role of usage of cardiovascular, antidiabetic, and other medications on risk and severity of COVID‐19. Analyses were adjusted for age, sex, and body mass index and for presence of relevant comorbidities. Individuals with hypertension taking calcium channel blockers had significantly increased risk (odds ratio (OR) = 1.73, 95% confidence interval (CI) 1.2–2.3) of manifesting symptoms of COVID‐19, whereas those taking angiotensin receptor blockers and diuretics had significantly lower disease risk (OR = 0.22, 95% CI 0.15–0.30 and OR = 0.30, 95% CI 0.19–0.58, respectively). Among those with type 2 diabetes, dipeptidyl peptidase‐4 inhibitors (OR = 6.02, 95% CI 2.3–15.5) and insulin (OR = 2.71, 95% CI 1.6–5.5) were more and glucosidase inhibitors were less prevalent (OR = 0.11, 95% CI 0.1–0.3) among with patients with COVID‐19. Drugs used in the treatment of hypertension and diabetes influence the risk of development of COVID‐19, but, not its severity. |
---|---|
ISSN: | 0009-9236 1532-6535 |
DOI: | 10.1002/cpt.2047 |